Movano Health Receives Nasdaq Delisting Notice, Plans Hearing Request

Movano Health received a delisting notice from Nasdaq due to a minimum bid price requirement and late filing of its Form 10-Q for Q1 2025. The company plans to request a hearing before a Nasdaq Hearings Panel to stay suspension and delisting, but there is no guarantee that it will regain compliance or maintain its listing.

Movano Health (NASDAQ: MOVE) has received a delisting notice from Nasdaq due to two significant compliance violations. The company's stock has failed to maintain a minimum bid price of $1.00 per share for 30 consecutive trading days, and it has also been late in filing its Form 10-Q for Q1 2025 [1]. Movano Health plans to request a hearing before a Nasdaq Hearings Panel to stay the suspension and delisting, but the outcome remains uncertain.

The delisting notice, issued on July 7, 2025, highlights Movano's failure to meet Nasdaq's minimum bid price requirement. This requirement is designed to ensure that the company's stock remains liquid and tradable. Additionally, the late filing of its Form 10-Q raises concerns about potential underlying financial reporting challenges or governance issues [2].

Movano Health, which was founded in 2018, is developing a suite of healthcare solutions and wearable medical devices. However, the company's current compliance issues could significantly impact its ability to raise capital and maintain its financial condition and business [2]. The company's stock has been trading below the $1.00 per share threshold for an extended period, and it is not eligible for the standard compliance period due to a reverse stock split conducted within the past year [1].

Investors should be aware of the significant uncertainty surrounding Movano Health's future. If the company is delisted, shareholders may face reduced liquidity, institutional investor restrictions, potential forced selling, and diminished market visibility. These factors typically accelerate share price deterioration. The standard stay period for the hearing request is only 22 days from the notice date, and there is no guarantee that the Nasdaq Hearings Panel will grant an extended stay or the continued listing request [1].

While Movano Health plans to request a hearing and an extended stay, the company acknowledges that there can be no assurance that the Panel will grant either request or that the company will be able to regain compliance and maintain its listing on Nasdaq [2]. The company has not provided a timeline for when it expects to regain compliance with Nasdaq's listing rules.

References:
[1] https://www.stocktitan.net/news/MOVE/movano-health-plans-to-timely-request-a-hearing-before-a-nasdaq-7jnvyqjmw9to.html
[2] https://www.marketscreener.com/quote/stock/MOVANO-INC-120780732/news/Movano-Health-Plans-to-Timely-Request-a-Hearing-Before-a-Nasdaq-Hearings-Panel-50493806/